Home Topics OMICs miRNA BIOMARKERS FOR DRUG-INDUCED LIVER INJURY miRNA BIOMARKERS FOR DRUG-INDUCED LIVER INJURY March 12, 2009 – Interview with David Galas, Ph.D., Senior Vice President of Strategic Partnerships, Institute for Systems Biology /wp-content/uploads/2018/09/gc254_3_12_2009.mp3 PodcastsResourcesBiomarkersCellular, Molecular and Developmental BiologyComputational biologyDiagnosisDrug-induced liver injuryHepatic injuryMedicine, Diagnosis, and TherapeuticsmiRNA (RNA isoforms)Molecular biologyMolecular biomarkerOrgan injuryRNA biologyRNA biomarkerRNA isoformsSystemic conditionsSystems biologyTechnology and Computational BiologyTrauma and injury Also of Interest Blood Biomarker Reveals Signs of Multiple Sclerosis Years Before StockWatch: PacBio Faces Uphill Climb as Q1 Revenue Falls Short Gene Network Interactions Shed Insight into Breast Cancer Onset and Development Bruker to Acquire NanoString with $392.6M Winning Bid New Insights Could Boost Immunotherapy for Rare Eye Cancer Skin in the Game: Oruka Takes on Blockbuster Drugs for Psoriasis, Dermatological Disorders Related Media AACR 2024: A Video Update from San Diego Carl Icahn States His Case for Change at Illumina on "Close to the Edge" Celebrating DNA: Matthew Cobb's Reflections on the Double Helix Emerging Markets Collaborate to Succeed in Post-Pandemic World The Sun Sets on AGBT: A Report from the Last Day Spatial, Sequencing, and Sun: A Report from Day 2 of AGBT Related Content Blood Biomarker Reveals Signs of Multiple Sclerosis Years Before StockWatch: PacBio Faces Uphill Climb as Q1 Revenue Falls Short Gene Network Interactions Shed Insight into Breast Cancer Onset and Development Bruker to Acquire NanoString with $392.6M Winning Bid